——Original title: Dried goods! Analysis of leading global vaccine industry companies in 2021 - GlaxoSmithKline : Vaccine business is under pressure, and the overall need to be transformed
Domestic major listed companies in this industry: Hualan Bio (002007), Zhifei Bio (300122), Kantai Bio (300601), Watson Bio (300142), CanSino (688185), Changchun Hi-Tech (000661), Fosun Pharma (600196), Jindike (688670), Olin Bio (688319), Baike Bio (688276)
Core data of this article: Market share, operating income, proportion of segmented products,
, comprehensive comparison of leading companies in the global human vaccine industry
At present, there are four leading companies in the world for human vaccines, namely GlaxoSmithKline, Merck, Pfizer, and French Sanofi . Their main businesses can be roughly divided into prescription drugs, vaccines and other; among them, Pfizer and Merck both conduct animal health care businesses, while the other two companies do not have similar businesses.
. GlaxoSmithKline: Vaccine business layout process
UK GlaxoSmithKline (GSK) is a leading enterprise in the UK biomedical industry. In 2000, GSK's predecessor company announced the merger and establishment of a brand new GSK company, making its fortune in prescription drugs. In 2009, GSK acquired Stifu Pharmaceutical Factory, which specializes in the manufacture of dermatological medicines. It also launched ViiV Healthcare with Pfizer, dedicated to the research and development and treatment of AIDS treatment drugs.
Through acquisition and commercial cooperation, GSK has gradually gained a leading position in the fields of breathing, HIV and vaccines. As a giant company in the pharmaceutical industry, its revenue ranks among the top ten in the world every year.
. GlaxoSmithKline: Vaccine business layout and operation status
—Shingrix is a vaccine star product
From the company's star products from 2019 to 2020, GlaxoSmithKline's main product is shingles vaccine Shingrix, which contributed more than one-quarter of the vaccine's operating income in 2020, followed by hepatitis vaccine Hepatitis, which contributed operating income of 1.209 billion pounds. From this point of view, GlaxoSmithKline's vaccine business is showing a diversified development trend and is less dependent on a single epidemic product.
—The commercial value of vaccines under development is high
From the perspective of the number of vaccine products under development, GSK company has a rich R&D pipeline echelon. Currently, there are 17 vaccine products under development, of which 1 is in the new drug registration stage, 7 is in the clinical stage, 5 is in the clinical stage II, and 4 is in the clinical stage. Based on the above information, GlaxoSmithKline has strong vaccine research and development capabilities and is more active and orderly.
From the perspective of the types of vaccine products under development, among the 17 vaccine products under development, new crown vaccine protein adjuvant accounts for 3; the largest number is the meningitis series vaccine, with a total of 3; followed by the respiratory syncytial virus series vaccine, with a total of 2. That is, one-third of the vaccines are targeting diseases that are particularly prevalent in in developing countries, including the three major infectious diseases highlighted by the WHO : HIV , malaria and tuberculosis , as well as other vaccines, including COPD treatment vaccines and respiratory syncytial virus (RSV) prevention vaccines, and other varieties with greater potential commercial value.
—Layout protein adjuvant avoid COVID-19 vaccine
In the layout of COVID-19 vaccine, GlaxoSmithKline mainly conducts the most stable vaccine adjuvant research and development and production.
According to the speech of Thomas Breuer, chief medical officer of the company's vaccine, in the early stages of the epidemic, senior leaders of GlaxoSmithKline quickly decided to make arrangements in the company's advantageous areas, namely the research, development and production of vaccine adjuvants. And according to the announcement of the company's official website in May 2020, GlaxoSmithKline announced the production of one billion doses of vaccine adjuvants to support the development of a variety of new crown vaccine candidates containing adjuvants.
According to the new crown vaccine market layout after GlaxoSmithKline, the company's business focuses on the production of relatively unpopular vaccine adjuvant, and uses its own financial advantages to directly invest in the new crown vaccine candidate vaccines of other companies. Although the operating income brought to GlaxoSmithKline by the direct "lying flat" method is not as high as that of Pfizer's operating income, it effectively avoids the potential risk of huge losses in R&D investment.
—Actively layout in China
After summarizing the data from the China Inspection Institute, it was shown that in 2020, the recombinant hepatitis B vaccine (Saccharomyces cerevisiae) had the largest batch issuance of the company's vaccine products in China, with a maximum batch issuance of 6.3207 million. In the first quarter of 2021, among the GSK's batch issuance of recombinant shingles vaccines, the largest batch issuance of 591,700.
From the perspective of layout in China, according to the official website of GlaxoSmithKline, its business in China covers 250 cities; Beijing, Shanghai, Guangzhou, Hangzhou and Chengdu are the five major business regional centers; 5 production bases are located in Shanghai, Suzhou , Hangzhou and Tianjin; a global R&D center is located in Shanghai Pudong .
In addition, GSK cooperated with leading biopharmaceutical companies and successively established Sino-US Tianjin Shike Pharmaceutical Co., Ltd. and Zhejiang Tianyuan Biopharmaceutical Co., Ltd. The latter is one of the leading vaccine production factories in China, producing multiple vaccines including influenza , meningitis, hemorrhagic fever, rabies , etc., and is also supplied to the Chinese market.
Overall, GSK is actively making arrangements in China and attaches great importance to the Chinese market.
, GlaxoSmithKline: Vaccine business operating performance
—Vaccine revenue is affected by the epidemic
From the perspective of the operating income of the vaccine business, GlaxoSmithKline's vaccine business revenue first grew and then fell. The main reason for the decline in the revenue of the vaccine business in 2020 is that the negative impact of the epidemic is that the suspension of work and production and the abandonment of research, development and production of the new crown vaccine have decreased.
—Vaccine R&D investment is relatively small
In 2020, GSK's R&D mainly focused on the prescription drug market, with the R&D department investing in US$1.056 billion, accounting for 81.42% of the total R&D expenses; the proportion of vaccine R&D expenses reached 13.72%, and the R&D expenses were invested at US$178 million; the R&D expenses of consumer health products reached US$63 million, accounting for 4.86% of the total R&D expenses.
In 2020, the company mainly focused on the research and development of anti-tumor drugs, among which major oncology research and development projects include Blenrep, feladilimab and bintrafusp alfa; equally important are a series of hepatitis B (HBV) vaccines in the second and third stages (GSK3228836) and anti-asthma drug development (GSK3511294).
, GlaxoSmithKline: Business strategy and development plan
In June 2021, GlaxoSmithKline announced the company's operation and R&D plans for the next 10 years at investor activities. The company's executives said it is expected that in mid-2022, GSK's Consumer Healthcare segment will be separated into an independent company. The split new GSK will focus on the development of innovative vaccines and drugs, with the goal of having a positive health impact on more than 2.5 billion people around the world over the next 10 years.
above data refer to the Forward Industry Research Institute's " In-depth Research and Investment Strategy Planning Analysis Report ". At the same time, the Forward Industry Research Institute also provides solutions such as industrial big data, industrial research, industrial chain consultation, industrial map, industrial planning, park planning, , industrial investment promotion, IPO investment feasibility research, prospectus writing and other solutions.
